NeurologyLive® Friday 5 — April 24, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more or watch now buttons for more details and information about each highlight.

1: Hormone Therapy in Alzheimer Disease Shows Biomarker Signals but Lacks Definitive Evidence: Amanda Rodrigues, MS

In an interview at AAN 2026, Amanda Rodrigues, MS, a medical student at at Santa Casa de São Paulo School of Medical Sciences, discussed the findings from a systematic review suggest potential biomarker-level benefits of estradiol-based hormone therapy in Alzheimer disease. [WATCH TIME: 3 minutes]

2: Using VISIBL-MS to Improve Early Detection and Diagnostic Pathways in Multiple Sclerosis

In an interview at AAN 2026, Jaime Imitola, MD, FAAN, FANA, professor of neurology and director of the UConn Comprehensive MS Center, discussed validation data on VISIBL-MS and its role in improving early MS recognition.

3: How Early Environmental Detection Could Refine Parkinson Disease Risk Models: Rodolfo Savica, MD, PhD

In an interview at AAN 2026, Rodolfo Savica, MD, PhD, an associate professor of neurology at Mayo Clinic Rochester, discussed why earlier detection of environmental risk in Parkinson disease remains difficult and how gene-environment research may help move the field forward. [WATCH TIME: 4 minutes]

4: NeuroVoices: Kate Rosenbluth, PhD, on Expanding Noninvasive Treatment for Essential Tremor With Cala kIQ Plus

In our latest NeuroVoices Q&A, Kate Rosenbluth, PhD, president at Cala Health, discussed the clinical role, evidence base, and future potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.

5: Addressing the True Burden of CIDP in Clinical Practice: Karen Lynch, MD, MRCPI

In a recent interview at AAN 2026, Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discussed the ongoing burden of CIDP, highlighting diagnostic challenges, treatment gaps, and the need for improved biomarkers and emerging therapies. [WATCH TIME: 3 minutes]

Don’t have time to read or watch a full video interview? Click here to check out our shorts!